Board of Directors

Steve Hoffman co-founded Tyme and has served as our Chief Executive Officer and Chairman since 2014. Mr. Hoffman has over 30 years of experience in biochemistry and physics, and has been the lead author on over 40 patents. For the last decade, he has focused on biopharmaceuticals for oncology, metabolic syndrome, and central nervous system disorders. Prior to working in biotech, he was involved in projects related to chemistry, aerospace and laser optics. In addition to leading the scientific development for his own companies, he has worked with multiple Fortune 500 healthcare companies, academic institutions, and the US government.

David Carberry has served as a member of our board of directors since 2017. Mr. Carberry has over 40 years of experience in the healthcare industry as a financial executive. From 2012 to 2016, Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. From 2008 to 2010, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company. From 1981 to 2008, Mr. Carberry served in a number of financial oversight roles within Johnson & Johnson, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider. Mr. Carberry received a Bachelor of Science degree in Accounting from La Salle University and Master in Business Administration in Finance from Drexel University. Mr. Carberry is a Certified Management Accountant.

Don DeGolyer has served as a member of our board of directors since May 2018. Mr. DeGolyer has over 30 years of experience in the pharmaceutical industry. Mr. DeGolyer currently serves on the board of directors of HLS Therapeutics, Inc., a specialty pharmaceutical company. He is also the Founder and Chief Executive Officer of Vertice Pharma, LLC, as well as a member of its board of directors. From 2013 to 2015, Mr. DeGolyer served as Chief Operating Officer of Endo Pharmaceuticals. Prior to Endo, he served as President & CEO of Sandoz North America. Mr. DeGolyer also held various leadership roles at Pfizer, Johnson & Johnson and Novartis. Mr. DeGoyler received a Bachelor of Science degree from University of Rochester and a Master in Business Administration from Fairleigh Dickinson University.r

Douglas A. Michels has served as a member of our board of directors since October 2018. Mr. Michels has over 39 years of experience in the healthcare industry. From 2004 to March 2018, Mr. Michels served as President and Chief Executive Officer of OraSure Technologies, Inc. as well as a member of its board of directors. Prior to OraSure, Mr. Michels spent 19 years with Johnson & Johnson during which time he held several executive positions, including President of Ortho Clinical Diagnostics International and President of Johnson & Johnson Healthcare Systems. In February 2010, Mr. Michels was appointed to the Presidential Advisory Council on HIV/AIDS by President Barack Obama. Mr. Michels currently serves on the board of directors of West Pharmaceutical Services, Inc., as well as a Trustee for Luke's University Hospital and Health Network and Miller-Keystone Blood Center, both in Bethlehem, Pennsylvania. He previously served on the Board of the National Blood Foundation, the Board of the National Committee for Quality Health Care and the Coalition to Protect America’s Health Care.

Gerald H. Sokol has served as a member of our board of directors since 2014. For 27 years Dr. Sokol served on the review staff of the Food and Drug Administration as a senior regulatory scientist and officer composing over 300 white papers, IND and NDA reviews, and opinion papers. Dr. Sokol attained his medical degree from Indiana University’s Combined Degree Program in Experimental Medicine with a Master of Science in Pharmacology and an MD. Dr. Sokol interned in Medicine at Temple University and attended the US Public Health Service Hospital in affiliation with the National Cancer Institute, Johns Hopkins, and the University of Maryland completing training in Internal Medicine. He then completed training at the Massachusetts General Hospital, Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology attaining Board Certification in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and later Quality Assurance and Utilization Review. He is also certified in Skin Cancer Medicine from the University of Queensland. Dr. Sokol is currently Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital and is a board member and partner of Florida Cancer Specialists and Research Institute. Dr. Sokol currently holds professorships in Medicine and Pharmacology at the Uniform Services University. Dr. Sokol is a lifetime fellow and board member of the American Cancer Society and a fellow of the American College of Clinical Pharmacology.

Paul Sturman has served as a member of our board of directors since 2017. Mr. Sturman has over 30 years of experience in the healthcare industry. Mr. Sturman is currently President and Chief Executive Officer of The Nature’s Bounty Company. From 2009 to 2014, Mr. Sturman served as Global President of Pfizer’s Consumer Healthcare business. Previously, Mr. Sturman served as President, North America for Johnson & Johnson after holding various executive positions with Pfizer and Warner Lambert. He currently serves on the board of directors of The Nature’s Bounty Company and has served as Chairman of the Consumer Healthcare Products Association (CHPA), a not-for-profit association representing the makers of over-the-counter medicines and promoting the role of non-prescription medicines. Mr. Sturman was also a member of the Board of Trustees of the Foundation for Morristown Medical Center. Mr. Sturman received a Bachelor of Science degree in Biology and a Master’s degree in Business Administration from Bucknell University.

Timothy C. Tyson has served as a member of our board of directors since 2015. Mr. Tyson has over 35 years of experience in the pharmaceutical industry. He currently serves as Chairman of Icagen Inc. Mr. Tyson has held numerous executive level positions at various pharmaceutical companies including Chairman and Chief Executive Officer of Avara Pharmaceutical Services, Inc., Chairman and Chief Executive Officer of Aptuit LLC, Chief Executive Officer, Chief Operating Officer and President of Valeant Pharmaceuticals International, President of Global Manufacturing and Supply for GlaxoSmithKline and ran Glaxo Dermatology and Cerenex Pharmaceuticals, and held executive positions at Bristol-Myers Squibb and Proctor and Gamble. Mr. Tyson has served on the board of directors of Valeant Pharmaceuticals International, The Pharmaceutical Research and Manufacturing Association, BICOM, the Chief Executive Officer Roundtable for the University of California at Irvine, the Dean’s Executive Forum at Cal State Fullerton, the Health Sector Advisory Board at Duke University, the International Leadership Forum of the International Society of Pharmaceutical Engineers and as a visiting lecturer at Cambridge University. Mr. Tyson received a Master in Business Administration and a Master of Science degree in Public Administration from Jacksonville State University. Mr. Tyson is also a graduate of the United States Military Academy at West Point.